Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 1.86
ZLCS's Cash to Debt is ranked higher than
60% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. ZLCS: 1.86 )
ZLCS' s 10-Year Cash to Debt Range
Min: 1.86   Max: No Debt
Current: 1.86

Equity to Asset 0.44
ZLCS's Equity to Asset is ranked higher than
58% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ZLCS: 0.44 )
ZLCS' s 10-Year Equity to Asset Range
Min: -1.78   Max: 0.76
Current: 0.44

-1.78
0.76
F-Score: 3
Z-Score: -18.99
M-Score: -3.97
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -252.60
ZLCS's Operating margin (%) is ranked higher than
61% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. ZLCS: -252.60 )
ZLCS' s 10-Year Operating margin (%) Range
Min: -12626.4   Max: -15.24
Current: -252.6

-12626.4
-15.24
Net-margin (%) -262.15
ZLCS's Net-margin (%) is ranked higher than
61% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. ZLCS: -262.15 )
ZLCS' s 10-Year Net-margin (%) Range
Min: -12504.49   Max: 89.09
Current: -262.15

-12504.49
89.09
ROE (%) -272.30
ZLCS's ROE (%) is ranked lower than
52% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. ZLCS: -272.30 )
ZLCS' s 10-Year ROE (%) Range
Min: -410.29   Max: 29.08
Current: -272.3

-410.29
29.08
ROA (%) -120.28
ZLCS's ROA (%) is ranked higher than
50% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. ZLCS: -120.28 )
ZLCS' s 10-Year ROA (%) Range
Min: -120.28   Max: 17.46
Current: -120.28

-120.28
17.46
ROC (Joel Greenblatt) (%) -1574.69
ZLCS's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. ZLCS: -1574.69 )
ZLCS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1574.69   Max: -103.23
Current: -1574.69

-1574.69
-103.23
Revenue Growth (%) -42.60
ZLCS's Revenue Growth (%) is ranked higher than
58% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. ZLCS: -42.60 )
ZLCS' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 34.5
Current: -42.6

0
34.5
EBITDA Growth (%) 2.70
ZLCS's EBITDA Growth (%) is ranked higher than
83% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. ZLCS: 2.70 )
ZLCS' s 10-Year EBITDA Growth (%) Range
Min: -60   Max: 54
Current: 2.7

-60
54
EPS Growth (%) -12.90
ZLCS's EPS Growth (%) is ranked higher than
74% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. ZLCS: -12.90 )
ZLCS' s 10-Year EPS Growth (%) Range
Min: -62.6   Max: 66.2
Current: -12.9

-62.6
66.2
» ZLCS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ZLCS Guru Trades in

ZLCS Guru Trades in

ZLCS Guru Trades in

Q4 2013

ZLCS Guru Trades in Q4 2013

Jim Simons 215,541 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with ZLCS



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.80
ZLCS's P/B is ranked higher than
87% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. ZLCS: 1.80 )
ZLCS' s 10-Year P/B Range
Min: 0.54   Max: 9.24
Current: 1.8

0.54
9.24
P/S 1.60
ZLCS's P/S is ranked higher than
93% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. ZLCS: 1.60 )
ZLCS' s 10-Year P/S Range
Min: 1.17   Max: 46
Current: 1.6

1.17
46
EV-to-EBIT 13.70
ZLCS's EV-to-EBIT is ranked higher than
71% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. ZLCS: 13.70 )
ZLCS' s 10-Year EV-to-EBIT Range
Min: 1.8   Max: 9.2
Current: 13.7

1.8
9.2

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 14.70
ZLCS's Price/Net Current Asset Value is ranked lower than
60% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. ZLCS: 14.70 )
ZLCS' s 10-Year Price/Net Current Asset Value Range
Min: 2.95   Max: 15.86
Current: 14.7

2.95
15.86
Price/Tangible Book 3.80
ZLCS's Price/Tangible Book is ranked higher than
72% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. ZLCS: 3.80 )
ZLCS' s 10-Year Price/Tangible Book Range
Min: 1.37   Max: 13.11
Current: 3.8

1.37
13.11
Price/Median PS Value 0.20
ZLCS's Price/Median PS Value is ranked higher than
97% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ZLCS: 0.20 )
ZLCS' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 2.51
Current: 0.2

0.24
2.51
Earnings Yield (Greenblatt) 7.30
ZLCS's Earnings Yield (Greenblatt) is ranked higher than
74% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. ZLCS: 7.30 )
ZLCS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 6.8   Max: 54.5
Current: 7.3

6.8
54.5
Forward Rate of Return (Yacktman) -209.20
ZLCS's Forward Rate of Return (Yacktman) is ranked higher than
51% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. ZLCS: -209.20 )
ZLCS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -367.8   Max: -301.2
Current: -209.2

-367.8
-301.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HGB.Germany
Zalicus, Inc., Delaware Corporation was incorporated in 2000. It is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The Company has a portfolio of proprietary clinical-stage product candidates targeting pain and has entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies. All of its proprietary product candidates are focused in the area of pain, which is an area of continuing medical need with potentially large commercial markets. It is focused on discovering and developing new compounds that selectively target neuronal calcium and sodium channels for the treatment of pain. The Company has successfully completed Phase 1 clinical trials evaluating the pharmacokinetics and safety profiles of several new formulations of Z160, and the new formulations have demonstrated substantial bioavailability improvements. Its next advanced product candidate is Z944, a novel oral T-type calcium channel blocker that seeks to develop for the treatment of pain indications. Until September of 2012, the company had also been advancing the development of Synavive, a product candidate to treat immuno-inflammatory disorders. The Company has also been performing discovery research and preclinical development activities on its proprietary selective ion channel modulators targeting the Nav1.7 sodium channel as well as N-type and T-type calcium channels. It competes against a range of pharmaceutical, biotechnology and life science companies that have greater resources than the company.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide